argenx SE - American Depositary Shares (NQ:ARGX)

797.62 -2.88 (-0.36%)

Streaming Delayed Price Updated: 1:55 PM EDT, Apr 10, 2026 Add to My Watchlist

Price and Volume

Volume	192,508
Open	808.27
Bid (Size)	796.85 (40)
Ask (Size)	798.07 (40)
Prev. Close	800.50
Today's Range	796.19 - 809.72
52wk Range	510.06 - 934.62
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story ↗

March 21, 2026

This biotech firm develops therapies for rare, complement-driven diseases, with a focus on autoimmune and inflammatory conditions.

Via The Motley Fool

This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch ↗

March 21, 2026

Cogent Biosciences develops targeted therapies for genetically defined diseases, focusing on precision medicine for rare cancers.

Via The Motley Fool

Performance

YTD	-5.0%	-5.0%
1 Month	+7.4%	+7.4%
3 Month	+0.3%	+0.3%
6 Month	-0.9%	-0.9%
1 Year	+41.4%	+41.4%

More News

argenx announces Annual General Meeting of Shareholders on May 6, 2026

March 20, 2026

From argenx SE

Via GlobeNewswire

This Specialized Heart Monitor Maker Just Caught the Eye of a Major Healthcare Fund ↗

March 20, 2026

Via The Motley Fool

Complementing the Future: A Deep Dive into Dianthus Therapeutics (DNTH) After Its Phase 3 Breakthrough

March 12, 2026

Via Finterra

DNTH Stock Soars After Early ‘Go’ Decision For Drug In Autoimmune Disorder Program, Boosting Wall Street Optimism For Potential Launch ↗

March 09, 2026

Via Stocktwits

argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline

March 06, 2026

From argenx SE

Via GlobeNewswire

Argenx (ARGX) 2026 Feature: The Anatomy of a Biotech Powerhouse Transitioning to Profitability

February 26, 2026

Via Finterra

argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update

February 26, 2026

From argenx SE

Via GlobeNewswire

argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis

February 26, 2026

From argenx SE

Via GlobeNewswire

argenx to Present at TD Cowen 46th Annual Healthcare Conference

February 23, 2026

From argenx SE

Via GlobeNewswire

argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026

February 19, 2026

From argenx SE

Via GlobeNewswire

Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash ↗

February 17, 2026

Via The Motley Fool

Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million ↗

February 17, 2026

Via The Motley Fool

Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake ↗

February 17, 2026

Via The Motley Fool

Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More ↗

February 17, 2026

Via The Motley Fool

Roivant Sciences (ROIV): Anatomy of a 15% Surge and the Future of the ‘Vant’ Model

February 06, 2026

Via Finterra

argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG

January 13, 2026

From argenx SE

Via GlobeNewswire

argenx Highlights 2026 Strategic Priorities

January 12, 2026

From argenx SE

Via GlobeNewswire

argenx to Present at 44th Annual J.P. Morgan Healthcare Conference

January 06, 2026

From argenx SE

Via GlobeNewswire

argenx Announces Leadership Transition Marking Next Evolution of Growth

January 05, 2026

From argenx SE

Via GlobeNewswire

Beyond the Bot: 2026 Marks the Great Rebalancing as Investors Pivot from AI Hype to Tangible Growth

January 02, 2026

Via MarketMinute

The 2026 Horizon: Technical Breakouts Signal a Sustained Bull Run in AI and Energy

December 31, 2025

Via MarketMinute

Biohaven Ltd. (BHVN): A High-Stakes Clinical Crossroad in Neuroscience and Immunology

December 26, 2025

Via PredictStreet

argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease

December 15, 2025

From argenx SE

Via GlobeNewswire

Frequently Asked Questions

Is argenx SE - American Depositary Shares publicly traded?

Yes, argenx SE - American Depositary Shares is publicly traded.

What exchange does argenx SE - American Depositary Shares trade on?

argenx SE - American Depositary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for argenx SE - American Depositary Shares?

The ticker symbol for argenx SE - American Depositary Shares is ARGX on the Nasdaq Stock Market

What is the current price of argenx SE - American Depositary Shares?

The current price of argenx SE - American Depositary Shares is 797.62

When was argenx SE - American Depositary Shares last traded?

The last trade of argenx SE - American Depositary Shares was at 04/10/26 01:55 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.